Jennifer S. Sun, PhD

April 19, 2022

Despite progress in the understanding of Tourette syndrome and similar disorders, no clear cause of TS has been identified, nor are there treatment options that completely eliminate symptoms.

February 15, 2022

With one-third of the 3.4 million US patients with epilepsy currently experience drug-resistant epilepsy, creating an urgent need for novel intervention strategies, such as stimulation approaches.

December 21, 2021

As Dravet syndrome is often nonresponsive to existing therapeutics, it can be a challenge to treat, and this refractory nature creates a great need for novel, innovative, and safe antiepileptic drugs for its treatment.

October 30, 2021

Continued improvement in the pharmacodynamics and pharmacokinetics of S1PR modulators, particularly in modulator-receptor selectivity, should improve therapeutic efficacy while reducing the potential for AEs.

August 19, 2021

γ-Hydroxybutyrate, known as GHB or oxybate, is a physiological compound present in the human body as both a precursor and degradation product of GABA.

June 16, 2021

ALS has only recently been associated with causative or disease-modifying mutations in 20 genes that encode proteins with diverse functions, with promising therapeutic targets including proteins in pathways that regulate protein homeostasis.

April 30, 2021

NMOSD is associated with elevated levels of the pleiotropic cytokine interleukin-6, making the cytokine an apt therapeutic target.

February 20, 2021

The PACAP pathway has shown promise as a potential novel therapeutic target in the treatment of migraine.

December 30, 2020

Patients with MS have an urgent need for therapies that can reverse neurologic disability by promoting remyelination, and RGMa inhibition may help meet that need.

October 24, 2020

Despite the continual epilepsy treatment landscape growth, there are only a few if any approved therapies for rare developmental and epileptic encephalopathies.